RPL22 and breast cancer: Somatic mutations in uL18 and uL16 have been described in T-cell acute lymphoblastic leukemia (T-ALL) [90]; mutations in uS19 (S15), uL15 (L27A) and eL22 have been described in 10–40% of multiple tumor types; and uL18 is also mutated in several cancers such as T-ALL like glioblastoma, melanoma, breast cancer and multiple myeloma [93].